Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Coronavirus Notebook: COVAX Exceeds Vaccine Funding Target, Canada OKs Mix-And-Match Dosing

Executive Summary

In a sign of growing support for more equitable vaccine distribution, many donors have pledged either money or doses to lower-income economies. The World Health Organization has granted emergency use listing to another Chinese vaccine, and Russia’s Sputnik V is to be produced in Bahrain for the MENA region.

You may also be interested in...



Coronavirus Update: Pfizer/BioNTech Commit 500m Doses For US Donations

The US obtained access to doses that it will donate to low- and low-middle-income countries, Merck & Co. is lining up government purchases of its Phase III drug, and Ocugen will submit a BLA in the US rather than pursue an EUA for Bharat's vaccine. Plus progress and setbacks for COVID-19 therapeutics. 

Coronavirus Update: India Waives Local Trials For Vaccines

India has waived the need for local clinical trials for COVID-19 vaccines already approved in certain other countries, while the WHO has added a Chinese vaccine to its emergency use list. Meanwhile, South Korea issues new guidance for local vaccine trials and Japan gives more money to COVAX. 

UNICEF Strikes Deal To Buy Russia’s Sputnik V Vaccine

A new procurement deal will add to the rollout of COVID-19 vaccines at global level. However, the leaders of the COVAX Facility say that by the end of June they will face a shortfall of 190 million doses, mainly because of the crisis in India, and are calling on wealthier countries to increase their donations.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

PS144417

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel